Rehmann Capital Advisory Group Raises Holdings in Bristol Myers Squibb Company $BMY

Rehmann Capital Advisory Group raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 6.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 36,700 shares of the biopharmaceutical company’s stock after purchasing an additional 2,372 shares during the period. Rehmann Capital Advisory Group’s holdings in Bristol Myers Squibb were worth $1,699,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Brighton Jones LLC raised its holdings in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. GAMMA Investing LLC raised its holdings in Bristol Myers Squibb by 18.8% in the 1st quarter. GAMMA Investing LLC now owns 39,685 shares of the biopharmaceutical company’s stock worth $2,420,000 after purchasing an additional 6,267 shares during the period. Continuum Advisory LLC raised its holdings in Bristol Myers Squibb by 88.6% in the 1st quarter. Continuum Advisory LLC now owns 3,268 shares of the biopharmaceutical company’s stock worth $199,000 after purchasing an additional 1,535 shares during the period. Archford Capital Strategies LLC raised its holdings in Bristol Myers Squibb by 56.4% in the 1st quarter. Archford Capital Strategies LLC now owns 18,472 shares of the biopharmaceutical company’s stock worth $1,127,000 after purchasing an additional 6,664 shares during the period. Finally, Silver Lake Advisory LLC raised its holdings in Bristol Myers Squibb by 0.9% during the first quarter. Silver Lake Advisory LLC now owns 30,225 shares of the biopharmaceutical company’s stock valued at $1,843,000 after acquiring an additional 272 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Down 0.4%

Shares of NYSE BMY opened at $44.36 on Thursday. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The company has a market cap of $90.29 billion, a P/E ratio of 17.89, a PEG ratio of 2.32 and a beta of 0.33. Bristol Myers Squibb Company has a 1 year low of $42.96 and a 1 year high of $63.33. The firm has a 50-day simple moving average of $45.92 and a two-hundred day simple moving average of $47.28.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.39. The business had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.6%. Bristol Myers Squibb’s payout ratio is 100.00%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on BMY shares. Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Daiwa Capital Markets cut Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target on the stock. in a report on Tuesday, August 5th. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Finally, Daiwa America lowered Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fourteen have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $57.23.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.